News

Veru Reports Fiscal 2024 First Quarter Financial Highlights

—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight…

2 years ago

Teleflex Announces Fourth Quarter 2023 Earnings Conference Call Information

WAYNE, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth…

2 years ago

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…

2 years ago

Safe Supply Streaming Announces Strategic Acquisition of 7% Stake in Leading Harm Reduction Company Safety Strips Tech Corp. and Provides Corporate Update

Toronto, Ontario--(Newsfile Corp. - February 8, 2024) - Safe Supply Streaming Co. Ltd. ("Safe Supply" or "the Company") (CSE: SPLY)…

2 years ago

AGFA HealthCare’s Enterprise Imaging XERO Viewer is Ranked #1 Best in KLAS in the Universal Viewer Category for 2024

The Best in KLAS report recognizes organizations who support healthcare providers that deliver optimized patient care, and the awards are…

2 years ago

Moelis & Company Reports Fourth Quarter and Full Year 2023 Financial Results; Declares Regular Quarterly Dividend of $0.60 Per Share

Fourth quarter GAAP revenues of $214.9 million; fourth quarter Adjusted revenues of $214.9 million, up 6% from the prior year…

2 years ago

Medexus Announces Fiscal Q3 2024 Results

Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host…

2 years ago

The Frigo Mint Company Tackles Cavity Crisis, Announces Launch of the Frigo Mint

New York, New York--(Newsfile Corp. - February 7, 2024) - Revolutionizing the daily oral care routine, The Frigo Mint Company…

2 years ago

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA…

2 years ago

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company…

2 years ago